CYP3A4 and stage 5 chronic kidney disease: Over D4-D7, recipient age at baseline, the main cause of end-stage renal disease, CYP3A phenotype, dyslipidemia at baseline and hematocrit, total bilirubin and plasma creatinine over the time period influenced tacrolimus exposure.